Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can rewiring fear expectations stop anxiety from coming back?

NCT ID NCT07753330

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study tests whether a new form of exposure therapy, called Expectancy Focused Exposure (EFE), can reduce anxiety symptoms and prevent fear from returning more effectively than traditional exposure therapy. Adults with anxiety disorders—such as social anxiety, panic disorder, generalized anxiety, or specific phobias—will receive either EFE or standard exposure therapy over about 10 weekly sessions. Researchers will track their anxiety levels before, during, and after treatment, and at 6, 12, and 18 months later, to see if EFE leads to longer-lasting improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Expectancy Focused Exposure (EFE), a psychological therapy that tests and challenges threat beliefs during exposure exercises
What this could lead to
If effective, this therapy could offer a more lasting treatment for anxiety disorders, reducing the chance that fear returns after therapy ends.
What could go wrong
The trial is relatively small and early, and results may not apply to everyone. Exposure exercises can cause temporary emotional discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 203 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Population Description The study sample will consist of adult participants from the general population seeking psychological treatment for anxiety-related problems. Participants will be recruited through multiple sources, including university mental health services, student wellbeing units, community mental health centers, social media advertisements, and other public outreach channels. Recruitment will be intentionally broad to maximize accessibility and ecological validity. Screening and Selection Procedures Eligibility will be determined through a multi-stage screening process. Initial Screening: DSM-5 Cross-Cutting Measures, Levels 1 and 2 Participants responding to recruitment will first complete the DSM-5 Level 1 Cross-Cutting Symptom Measure (APA, 2013; Spanish version APA, 2014). This self-report instrument includes 23 items assessing 13 domains of psychopathology over the past 14 days using a 5-point Likert scale. It has shown good reliability and clinical utility in prior studies (APA, 2014; Bravo et al., 2018). Participants who meet threshold criteria for anxiety-related symptoms on the Level 1 measure will then complete the corresponding DSM-5 Level 2 anxiety measures to further characterize symptom severity. Disorder-Specific Symptom Assessment, Level 3 Participants who meet screening criteria on Levels 1 and 2 will complete disorder-specific symptom scales according to the anxiety disorder suspected or reported, including measures for social anxiety disorder, specific phobia, generalized anxiety disorder, and panic disorder with or without agoraphobia. Diagnostic Assessment Participants who remain eligible after the screening and disorder-specific symptom assessment will undergo a structured clinical interview using the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5). The ADIS-5 will be used to establish the principal anxiety disorder diagnosis and to assess exclusion criteria, including psychotic disorder, bipolar disorder, high suicide risk, and severe or uncontrolled substance use disorder. Inclusion Criteria: Participants must meet all of the following criteria: * Age between 18 and 70 years. * Seeking treatment for anxiety-related difficulties. * Meet DSM-5 diagnostic criteria for a principal anxiety disorder, including: social anxiety disorder, specific phobia, generalized anxiety disorder, panic disorder with or without agoraphobia. * Diagnosis will be established using the ADIS-5 structured clinical interview. * For participants with generalized anxiety disorder, treatment will focus on the principal anxiety problem identified during assessment. * Present clinically significant anxiety symptoms associated with the principal diagnosis. * If currently taking anxiolytic medication, the dosage must have remained stable for at least three months before the start of treatment and should be maintained during the treatment phase whenever possible. * Willingness and ability to participate in weekly psychotherapy sessions and complete all study assessments. * Provide informed consent. Exclusion Criteria: Participants will be excluded if any of the following conditions are present: * Current psychotic disorder. * Current manic or hypomanic episode, consistent with bipolar disorder. * High suicide risk requiring immediate clinical intervention. * Severe or uncontrolled substance use disorder. * Concurrent participation in psychological treatment specifically targeting the anxiety disorder during the study period. * Medical conditions that contraindicate exposure procedures (e.g., severe cardiovascular conditions). * Cognitive impairment or insufficient language proficiency that would interfere with participation in psychotherapy or completion of assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Facultad de Ciencias Sociales, Universidad de Chile

    RECRUITING

    Santiago, Santiago Metropolitan, 7800284, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.